ADRB1 and hydrops fetalis: HF therapy has been improved greatly over the past two decades, particularly with the use of angiotensin-converting enzyme inhibitors and β1-adrenergic receptor (β1AR) antagonists, which inhibit pathological remodeling and apoptosis of cardiomyocytes4,5.